Loading
BBI-940 / Advanced Breast Cancer / Metastatic Breast Cancer · Phase 1 Trial
ClinicalTrials.gov · August 4, 2026
Early or partial results. Treat as a signal, not a conclusion.
This is a registry record for a terminated first-in-human Phase 1 trial of BBI-940, a kinesin oral molecular degrader, in advanced or metastatic breast cancer. No results are reported in this registry entry. The study enrolled 8 participants and was terminated; clinical outcomes remain unpublished.
Phase 1, Interventional, Non Randomized, Sequential, Open label, Treatment purpose. Breast Cancer, Metastatic Breast Cancer, Advanced Breast Cancer; age from 18 Years. Intervention: Parts 1A, 1B. BBI-940 Monotherapy Escalation; Part 2A. BBI-940 in Combination with Fulvestrant (ER+/HER2-…; Part 2B. BBI-940 Monotherapy Expansion (ER+/HER2- Breast Ca…; Part 2C. BBI-940 Monotherapy Expansion (TNBC-LAR). n = 8. 8 sites: United States.
This is a registry record for a terminated first-in-human Phase 1 trial of BBI-940, a kinesin oral molecular degrader, in advanced or metastatic breast cancer. No results are reported in this registry entry. The study enrolled 8 participants and was terminated; clinical outcomes remain unpublished.
Study terminated; no efficacy, safety, or tolerability results reported in registry record
The source did not state who this applies to in practice.
Clinical trial registry record for terminated Phase 1 study with no results reported; preliminary status reflects early-stage investigation without outcome data.
As stated by the source record.
Quoted from the source exactly as published.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no key findings. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT07408089). This is a study registration, not published results. Lead sponsor: Boundless Bio, Inc.. Recruitment status: TERMINATED. Phase: PHASE1. Study type: INTERVENTIONAL. Enrollment: 8 participants (ACTUAL). Conditions: Breast Cancer, Metastatic Breast Cancer, Advanced Breast Cancer. Interventions: DRUG: BBI-940; DRUG: Fulvestrant. Primary outcome measures: Rate of dose limiting toxicities (DLTs) in each BBI-940 monotherapy dose escalation cohort. , First 28 days of study treatment (through end of Cycle 1).; Incidence of treatment emergent adverse events (TEAEs) in each dose group and overall as assessed by CTCAE version 5.0. , First dose of study treatment through 30 days after the last dose of study treatment.; Incidence of study treatment discontinuation and/or interruption by dose group and overall. , First dose of study treatment through 30 days after the last dose of study treatment.. Brief summary: This is a first-in-human, open-label, Phase 1 study evaluating BBI-940, an investigational kinesin oral molecular degrader, administered as monotherapy or in combination with fulvestrant in adults with advanced or metastatic breast cancer.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.